ArticleCancer cell international2026
Bioinformatics analysis of PFKFB family in pan-cancer and preliminary exploration of PFKFB4 in bladder cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe phosphofructokinase-fructose bisphosphatases (PFKFBs) family is critical in tumors and the immune system. Nevertheless, the involvement of the PFKFB family genes in the immune microenvironment and prognosis of tumor patients has not been investigated using genomic and transcriptomic analyses.
methodsWe collected data from 33 cancers and comprehensively analyzed the PFKFB family genes for abnormal expression, genomic alterations, diagnostic and prognostic roles, subcellular localization, pathway enrichment, immune microenvironment, association with immune checkpoints, and drug sensitivity in the disease, as well as predicting patients' immunotherapeutic response to ICI and targeting of small molecule drugs, and performed the above results by immunohistochemical staining, pathological sections, and experiments for validation. Finally, we experimentally confirmed the role of PFKFB4 in bladder cancer.
resultsWe found the differential expression and diagnostic biomarker value of PFKFBs family members in pan-cancer, and also found that they play a key role in pan-cancer in relation to the tumor microenvironment. PFKFBs are closely associated with common immune checkpoints, TMB and MSI, and PFKFBs family members can predict immunotherapy response in patients with a wide range of cancers. Finally, it was experimentally determined that knockdown of PFKFB4 gene expression inhibited proliferation and invasion of bladder cancer cells.
conclusionsOur study highlights the great potential of PFKFBs as prognostic and immunotherapeutic response biomarkers, which may pave the way for further investigation of the tumor infiltration mechanism and therapeutic potential of PFKFBs in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.